IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA)
CUSIP: 462260100
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 415,431,143
- Total 13F shares
- 220,039,758
- Share change
- -19,345,465
- Total reported value
- $378,480,610
- Put/Call ratio
- 101%
- Price per share
- $1.72
- Number of holders
- 244
- Value change
- -$103,966,458
- Number of buys
- 125
- Number of sells
- 151
Quarterly Holders Quick Answers
What is CUSIP 462260100?
CUSIP 462260100 identifies IOVA - IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 462260100:
Top shareholders of IOVA - IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Wayne P. Rothbaum |
3/4/5
|
Director |
—
mixed-class rows
|
28,167,333
mixed-class rows
|
$257,731,097 | — | 01 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.7%
|
27,777,778
|
$92,500,000 | — | 31 Mar 2025 | |
| MHR FUND MANAGEMENT LLC |
13F
|
Company |
5.9%
|
24,417,103
|
$81,308,953 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
24,314,578
|
$80,967,543 | — | 31 Mar 2025 | |
| PERCEPTIVE ADVISORS LLC |
13D/G
13F
|
Company |
3.8%
|
12,808,788
|
$45,599,285 | -$33,120,382 | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
11,041,322
|
$36,767,602 | — | 31 Mar 2025 | |
| Long Focus Capital Management, LLC |
13F
|
Company |
2.2%
|
9,250,055
|
$30,802,683 | — | 31 Mar 2025 | |
| Hood River Capital Management LLC |
13F
|
Company |
2.2%
|
9,216,040
|
$30,689,413 | — | 31 Mar 2025 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.9%
|
7,785,000
|
$25,924,050 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.4%
|
5,968,298
|
$19,878,539 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
1.4%
|
5,777,344
|
$19,238,556 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
5,571,902
|
$18,554,434 | — | 31 Mar 2025 | |
| Invenomic Capital Management LP |
13F
|
Company |
1.3%
|
5,489,799
|
$18,281,031 | — | 31 Mar 2025 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
1.2%
|
4,791,235
|
$15,955,000 | — | 31 Mar 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
1.1%
|
4,694,122
|
$15,631,427 | — | 31 Mar 2025 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
1.1%
|
4,407,713
|
$14,677,684 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.97%
|
4,018,374
|
$13,381,185 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.85%
|
3,511,400
|
$11,692,962 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.84%
|
3,506,108
|
$11,679,793 | — | 31 Mar 2025 | |
| Palo Alto Investors LP |
13F
|
Company |
0.77%
|
3,211,314
|
$10,693,676 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.73%
|
3,017,185
|
$10,047,226 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.65%
|
2,708,582
|
$9,019,578 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.6%
|
2,496,749
|
$8,314,173 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.58%
|
2,404,080
|
$8,006,000 | — | 31 Mar 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.58%
|
2,400,000
|
$7,991,999 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.56%
|
2,343,563
|
$7,804,064 | — | 31 Mar 2025 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
0.46%
|
1,930,020
|
$6,427,000 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.44%
|
1,847,741
|
$6,152,978 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.43%
|
1,802,193
|
$6,001,303 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.43%
|
1,800,000
|
$5,994,000 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.42%
|
1,732,803
|
$5,770,234 | — | 31 Mar 2025 | |
| Merrill A. Mcpeak |
3/4/5
|
Director |
—
mixed-class rows
|
618,783
mixed-class rows
|
$5,661,865 | — | 01 Mar 2024 | |
| RICE HALL JAMES & ASSOCIATES, LLC |
13F
|
Company |
0.38%
|
1,569,212
|
$5,225,476 | — | 31 Mar 2025 | |
| B Group, Inc. |
13F
|
Company |
0.36%
|
1,500,000
|
$4,995,000 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.31%
|
1,280,250
|
$4,263,232 | — | 31 Mar 2025 | |
| APIS CAPITAL ADVISORS, LLC |
13F
|
Company |
0.31%
|
1,277,000
|
$4,252,410 | — | 31 Mar 2025 | |
| C WorldWide Group Holding A/S |
13F
|
Company |
0.3%
|
1,260,000
|
$4,196,000 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.3%
|
1,258,561
|
$4,191,008 | — | 31 Mar 2025 | |
| Orion Investment Co |
13F
|
Company |
0.28%
|
1,176,853
|
$3,918,920 | — | 31 Mar 2025 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.28%
|
1,170,745
|
$3,899,000 | — | 31 Mar 2025 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.27%
|
1,121,417
|
$3,734,319 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.22%
|
920,461
|
$3,270,603 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.23%
|
972,689
|
$3,239,054 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.22%
|
918,210
|
$3,057,638 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.21%
|
886,738
|
$2,952,837 | — | 31 Mar 2025 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.21%
|
858,570
|
$2,859,037 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.16%
|
685,146
|
$2,281,536 | — | 31 Mar 2025 | |
| QVT Financial LP |
13F
|
Company |
0.16%
|
678,564
|
$2,259,618 | — | 31 Mar 2025 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.16%
|
647,827
|
$2,157,264 | — | 31 Mar 2025 | |
| CAPITAL FUND MANAGEMENT S.A. |
13F
|
Company |
0.14%
|
599,871
|
$1,997,570 | — | 31 Mar 2025 |
Institutional Holders of IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA) as of Q2 2025
As of 30 Jun 2025,
IOVANCE BIOTHERAPEUTICS, INC. - COMMON STOCK (IOVA) was held by
244 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
220,039,758 shares.
The largest 10 holders included
MHR FUND MANAGEMENT LLC, VANGUARD GROUP INC, BlackRock, Inc., Long Focus Capital Management, LLC, STATE STREET CORP, MILLENNIUM MANAGEMENT LLC, Invenomic Capital Management LP, MORGAN STANLEY, GEODE CAPITAL MANAGEMENT, LLC, and RENAISSANCE TECHNOLOGIES LLC.
This page lists
247
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
292
Q2 2025 holders
244
Holder diff
-48
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.